Back to today’s briefing

Story perspectives

GSK's $1B Biotech Deal Fuels Cancer Research Ambitions

1/15/2025

44 3

Summary

Story summary

GSK's Chief Scientific Officer, Tony Wood, unveiled ambitious plans to deepen partnerships in genetic research targeting gastrointestinal cancers. The company’s $1 billion acquisition of precision biotech IDRx signals a bold move, while GSK and Sanofi's CEOs stressed the critical need for transparency in vaccine dialogues at the J.P. Morgan Healthcare Conference.

1 of 1

Story summary

GSK's Chief Scientific Officer, Tony Wood, unveiled ambitious plans to deepen partnerships in genetic research targeting gastrointestinal cancers. The company’s $1 billion acquisition of precision biotech IDRx signals a bold move, while GSK and Sanofi's CEOs stressed the critical need for transparency in vaccine dialogues at the J.P. Morgan Healthcare Conference.